Recombinant adenoviruses carrying transgenes

Patent metadata

Field	Value
Publication number	US-11253608-B2
Application number	US-201815991745-A
Country	US
Kind code	B2
Filing date	May 29, 2018
Priority date	May 26, 2017
Publication date	Feb 22, 2022
Grant date	Feb 22, 2022

Abstract

Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

First claim

The invention claimed is:

1. A recombinant adenovirus comprising a nucleotide sequence inserted in an IX-E2 insertion site, wherein the IX-E2 insertion site is located between the stop codon of adenovirus IX gene and the stop codon of adenovirus IVa2 gene, wherein the nucleotide sequence comprises a promoter, a transgene, and a second polyadenylation signal and the recombinant adenovirus comprises in a 5′ to 3′ orientation:
(i) a first polyadenylation signal;
(ii) the promoter;
(iii) the transgene;
(iv) the second polyadenylation signal; and
(v) a third polyadenylation signal;
wherein the transgene is operably linked to the promoter, and wherein the first polyadenylation signal is the polyadenylation signal of the IX gene, the second polyadenylation signal is the polyadenylation signal of the transgene, and the third polyadenylation signal is the polyadenylation signal of the adenovirus IVa2 gene, and a fourth polyadenylation signal is between the first polyadenylation signal and the promoter;
wherein the fourth polyadenylation signal is in the opposite transcriptional direction of the first polyadenylation signal, and
wherein the recombinant adenovirus is a type 5 adenovirus (Ad5) or a type 35 adenovirus (Ad35);
wherein the nucleotide sequence is inserted between nucleotides 4029 and 4093 of the Ad5 genome (SEQ ID NO: 1) or between nucleotides 3899 and 3970 of the Ad35 genome (SEQ ID NO: 41).

2. The recombinant adenovirus of claim 1 , wherein the recombinant adenovirus further comprises a nucleotide sequence inserted in an E1b-19K insertion site, an E3 insertion site, or an E4 insertion site.

3. The recombinant adenovirus of claim 1 , wherein the recombinant adenovirus further comprises a nucleotide sequence inserted in an L5-E4 insertion site, wherein the L5-E4 insertion site is located between the stop codon of adenovirus fiber gene and the stop codon of ORF6 or ORF6/7 of adenovirus E4 gene.

4. The recombinant adenovirus of claim 1 , wherein the recombinant adenovirus selectively replicates in a hyperproliferative cell.

5. The recombinant adenovirus of claim 1 , wherein the recombinant adenovirus selectively expresses the transgene in a hyperproliferative cell.

6. A method of inhibiting tumor growth in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the recombinant adenovirus of claim 1 to inhibit growth of the tumor.

7. A recombinant adenovirus comprising a nucleotide sequence inserted in an L5-E4 insertion site, wherein the L5-E4 insertion site is located between the stop codon of adenovirus fiber gene (fiber L5 gene) and the stop codon of ORF6 or ORF6/7 of adenovirus E4 gene, wherein the nucleotide sequence comprises a promoter, a transgene, and a second polyadenylation signal and the recombinant adenovirus comprises in a 5′ to 3′ orientation:
(i) a first polyadenylation signal;
(ii) the promoter;
(iii) the transgene;
(iv) the second polyadenylation signal; and
(v) a third polyadenylation signal;
wherein the transgene is operably linked to the promoter, and wherein the first polyadenylation signal is the polyadenylation signal of the fiber (L5) gene, the second polyadenylation signal is the polyadenylation signal of the transgene, the third polyadenylation signal is the polyadenylation signal of the ORF6 or ORF6/7 of the adenovirus E4 gene, and a fourth polyadenylation signal is between the first polyadenylation signal and the promoter;
wherein the fourth polyadenylation signal is in the opposite transcriptional direction of the first polyadenylation signal, and
wherein the recombinant adenovirus is a type 5 adenovirus (Ad5) or a type 35 adenovirus (Ad35);
wherein the nucleotide sequence is inserted between nucleotides 32785 to 32916 of the Ad5 genome (SEQ ID NO: 1) or between nucleotides 31799 and 31821 of the Ad35 genome (SEQ ID NO: 41)..

8. The recombinant adenovirus of claim 7 , wherein the recombinant adenovirus further comprises a nucleotide sequence inserted in an E1b-19K insertion site, an E3 insertion site, or an E4 insertion site.

9. The recombinant adenovirus of claim 7 , wherein the recombinant adenovirus further comprises a nucleotide sequence inserted in an IX-E2 insertion site, wherein the IX-E2 insertion site is located between the stop codon of an adenovirus IX gene and the stop codon of an adenovirus IVa2 gene.

10. The recombinant adenovirus of claim 7 , wherein the recombinant adenovirus selectively replicates in a hyperproliferative cell.

11. The recombinant adenovirus of claim 7 , wherein the recombinant adenovirus selectively expresses the transgene in a hyperproliferative cell.

12. A method of inhibiting tumor growth in a subject in need thereof, wherein the method comprises administering to the subject to an effective amount of the recombinant adenovirus of claim 7 to inhibit growth of the tumor.

13. A recombinant adenovirus comprising a first nucleotide sequence inserted in an IX-E2 insertion site and a second nucleotide sequence inserted in an L5-E4 insertion site, wherein the IX-E2 insertion site is located between the stop codon of adenovirus IX gene and the stop codon of adenovirus IVa2 gene, and wherein the L5-E4 insertion site is located between the stop codon of adenovirus fiber gene (L5) and the stop codon of ORF6 or ORF6/7 of adenovirus E4 gene, wherein the first nucleotide sequence comprises a first promoter, a first transgene, and a second polyadenylation signal and the recombinant adenovirus comprises in a 5′ to 3′ orientation:
(i) a first polyadenylation signal;
(ii) the first promoter;
(iii) the first transgene;
(iv) the second polyadenylation signal; and
(v) a third polyadenylation signal;
wherein the first transgene is operably linked to the first promoter, and wherein the first polyadenylation signal is the polyadenylation signal of the IX gene, the second polyadenylation signal is the polyadenylation signal of the first transgene, and the third polyadenylation signal is the polyadenylation signal of the adenovirus IVa2 gene, and
a fourth polyadenylation signal is between the first polyadenylation signal and the first promoter;
wherein the fourth polyadenylation signal is in the opposite transcriptional direction of the first polyadenylation signal, and
wherein the recombinant adenovirus is a type 5 adenovirus (Ad5) or a type 35 adenovirus (Ad35);
wherein the first nucleotide sequence is inserted between nucleotides 4029 and 4093 of the Ad5 genome (SEQ ID NO: 1) or between nucleotides 3899 and 3970 of the Ad35 genome (SEQ ID NO: 41).

14. The recombinant adenovirus of claim 13 , wherein the second nucleotide sequence is inserted between nucleotides 32785 to 32916 of the Ad5 genome (SEQ ID NO: 1) or between nucleotides 31799 and 31821 of the Ad5 genome (SEQ ID NO: 41).

15. The recombinant adenovirus of claim 13 , wherein the second nucleotide sequence comprises a second transgene.

16. The recombinant adenovirus of claim 15 , wherein the second nucleotide sequence further comprises a second promoter, wherein the second transgene is operably linked to the second promoter.

17. The recombinant adenovirus of claim 13 , wherein the second nucleotide sequence comprises a second promoter, a second transgene, and a sixth polyadenylation signal and the recombinant adenovirus comprises, in a 5′ to 3′ orientation:
(i) a fifth polyadenylation signal;
(ii) the second promoter;
(iii) the second transgene;
(iv) the sixth polyadenylation signal; and
(v) a seventh polyadenylation signal;
wherein the second transgene is operably linked to the second p

Assignees

• Epicentrx Inc

Inventors

• Larson Christopher
• Oronsky Bryan
• Reid Tony R

Classifications

• C12N2710/10321

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N2710/10332

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N2830/50

  regulating RNA stability, not being an intron, e.g. poly A signal · CPC title

• C12N2800/107

  for mammalian · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title